Clinical trial · Interventional
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Closed due to insufficient recruitment
Summary
Brief summary (as posted)
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Iressa (Gefitinib) | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Time to progression (2 years after Last patient in)
Secondary outcomes (2)
- measure
- Modalities of relapse or progression (2 years after Last patient in)
- measure
- Overall survival (2 years after Last patient in)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically Confirmed Non Small Cell Lung Cancer. * Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy). * Chemotherapy with regimens containing cisplatin or carboplatin is mandatory * Response to combined therapy Exclusion Criteria: * No previous treatment with ZD1839 or any other EGFR-targeted therapy * No progressive disease after combined therapy for locally advanced NSCLC * No presence of metastatic disease * No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * Any unresolved chronic toxicity from previous anticancer therapy.
References
Publications (0)
Data not yet available